Spago Nanomedical Q2: Milestone almost concluded, continued cost control crucial - Redeye

Redeye comments on Spago Nanomedical’s Q2 2023 report. We note that a complete analysis of the study results of SPAGOPIX-02 still awaits. In the short- to medium-term, positive efficacy read-out from SPAGOPIX-02 would provide a moderate upward swing in the share as the cash position is slowly running short, which should fuel some worries about the continued financing of the company and its projects.

Länk till analysen i sin helhet: https://www.redeye.se/research/926916/spago-nanomedical-q2-milestone-almost-concluded-continued-cost-control-crucial?utm_source=finwire&utm_medium=RSS